LSP PROJECT REPORT DEVELOPMENT OF HEPG CELL LINE WITH HUMAN NTCP GENE

No Thumbnail Available

Date

2024

Journal Title

Journal ISSN

Volume Title

Publisher

Nazarbayev University School of Medicine

Abstract

Hepatitis B virus (HBV) is one of the most common viral infections of the liver. There are 296 million people around the world with chronic hepatitis B and 1.5 million new cases emerge each year (WHO on Hepatitis B, 2021). Also, complications of hepatitis B virus such as liver cirrhosis and hepatocellular carcinoma were the cause of 820 000 deaths in 2019. It creates a significant economic and social burden, especially in developing countries. Until the 2010s the proper mechanism of viral internalization of hepatitis B virus was not properly understood. However, discovery of Na+-taurocholate cotransporting polypeptide (NTCP) protein allowed better understanding of the process as well as new possibilities in treatment. Common anti-HBV treatment is usually antiretroviral utilizing its usage of reverse transcriptase. The discovery of a specific viral entry point may allow development of new treatment options. However, expression of NTCP is downregulated in in vitro hepatocytes. This poses an obstacle in creating a testing field for medication options. Sadly, during this research the results were not achieved due to shortage of time and difficulties with competent cells.

Description

Keywords

Type of access:, Hepatitis B virus

Citation

Irgaliyev, A. (2024). LSP project report Development of HepG cell line with human NTCP gene. Nazarbayev University School of Medicine